89368-12-7

Basic information

• Product Name: 1-(4-bromo-2-methoxyphenyl)ethanone
• Synonyms: 1-(4-bromo-2-methoxyphenyl)ethanone
• CAS NO: 89368-12-7
• Molecular Formula: C₉H₉BrO₂
• Molecular Weight: 229.07056
• Mol File: 89368-12-7.mol
• Article Data: 18

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 1-(4-bromo-2-methoxyphenyl)ethanone(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-bromo-2-methoxyphenyl)ethanone(89368-12-7)
• EPA Substance Registry System: 1-(4-bromo-2-methoxyphenyl)ethanone(89368-12-7)

Safety Data

• RIDADR: 3261
• HazardClass: 8
• PackingGroup: Ⅲ
• Hazardous Substances Data: 89368-12-7(Hazardous Substances Data)

Usage

Preparation

Obtained by reaction of acetic anhydride with m-bromoanisole in the presence of lithium perchlorate at 100° for 5 h (40%).

Upstream product

• 591-20-8 3-Bromophenol 
• 2398-37-0 3-methoxyphenyl bromide 
• 75-36-5 acetyl chloride 
• 108-24-7 acetic anhydride 
• 579-74-8 2-Methoxyacetophenone 
• 30186-18-6 4'-bromo-2'-hydroxyacetophenone 
• 74-88-4 methyl iodide 
• 77-78-1 dimethyl sulfate 
• 35065-86-2 3-bromophenyl acetate 

Downstream Products

• 638214-65-0 1-[2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]ethan-1-one 
• 252561-75-4 2-bromo-1-(4-bromo-2-methoxyphenyl)ethan-1-one 

Relevant articles and documents

DOCK1-INHIBITING COMPOUND AND USE THEREOF

Provided is a compound that is usable as an active ingredient of an anticancer agent. Preferably provided is a compound that has DOCK1-inhibiting activity and exerts an anticancer effect based on the activity. A compound represented by the following formula (A) or a salt thereof: wherein X represents a carbon atom or a nitrogen atom; Y represents an oxygen atom, a hydroxy group, or a hydrocarbon group; R1 and R2 are different, and each represents a hydrogen atom or a group represented by the following formula (A-1): (wherein R6 represents a pyrrolidino group or a phenyl group, and n2 is 0 or 1) ; R3 represents -CO-R7 (wherein R7 is an alkoxy group, an alkyl group, or an alkylamino group), a 1,3-oxazole group, an alkylhydroxy group, a hydrogen atom, or an oxygen atom; R4 represents a hydrogen atom, an oxygen atom, or a hydrocarbon group in which one or more hydrogen atoms may be replaced by one or more substituents; R5 represents a halogen atom, a halogenated alkyl group, or a halogenated alkylthio group; and n1 is an integer of 0 to 5; and

BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE

The present disclosure relates to bifunctional compounds, which find utility as modulators of SMARCA2 or BRM (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a ligand that binds to the Von Hippel-Lindau E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

PHENYL SUBSTITUTED PYRAZOLES AS MODULATORS OF RORgT

The present invention comprises compounds of Formula I. wherein: R1, R3, R4, R5, R6, R7, R8, and Q are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-γ-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.